← All trials
NCT05804383
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2023
- Primary completion
- Oct 15, 2024
- Completion date
- Nov 15, 2024
- First posted
- Apr 7, 2023
- Last posted
- Oct 19, 2023
- Enrollment
- 50
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allyx TherapeuticsLead sponsor
- National Institute on Aging (NIA)Collaborator
- Yale UniversityCollaborator
- Yale UniversityStudy director
- Yale UniversityOfficial
- Yale UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.